ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.16
0.45%
US Tech 100
20,877.20
1.72%
S&P 500
5,996.66
1.00%
US Dollar vs CAD
1.44121
0.77%
Bitcoin
102,382.78
0.33%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Gyre Therapeutics Inc (GYRE)

  7. Gyre Therapeutics Inc (GYRE) News

GYRE

Gyre Therapeutics (GYRE)

Gyre Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GYRE
DateTimeSourceHeadlineSymbolCompany
01/16/20253:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
01/14/20253:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
01/10/20253:01PMEdgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:GYREGyre Therapeutics Inc
01/08/20253:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
01/07/20253:01PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
01/06/20253:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
01/06/20256:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
01/06/20256:00AMGlobeNewswire Inc.Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of DirectorsNASDAQ:GYREGyre Therapeutics Inc
01/02/20253:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
12/30/20243:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
12/26/20243:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
12/23/20243:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
12/19/20243:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
11/27/20243:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
11/27/20243:21PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GYREGyre Therapeutics Inc
11/24/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GYREGyre Therapeutics Inc
11/14/20243:39PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GYREGyre Therapeutics Inc
11/13/20245:00AMGlobeNewswire Inc.Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
10/22/20243:05PMGlobeNewswire Inc.Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver FibrosisNASDAQ:GYREGyre Therapeutics Inc
10/01/20243:05PMGlobeNewswire Inc.Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor ConferenceNASDAQ:GYREGyre Therapeutics Inc
09/06/20247:31AMEdgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GYREGyre Therapeutics Inc
09/06/20247:15AMEdgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GYREGyre Therapeutics Inc
09/04/20243:05PMGlobeNewswire Inc.Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:GYREGyre Therapeutics Inc
08/13/20245:00AMGlobeNewswire Inc.Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
08/09/20246:00AMGlobeNewswire Inc.Gyre Therapeutics to Present at Sidoti Virtual Investor ConferenceNASDAQ:GYREGyre Therapeutics Inc
08/08/20243:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
08/08/20243:05PMGlobeNewswire Inc.Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of DirectorsNASDAQ:GYREGyre Therapeutics Inc
07/02/20243:05PMGlobeNewswire Inc.Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated ThrombocytopeniaNASDAQ:GYREGyre Therapeutics Inc
06/18/20243:05PMGlobeNewswire Inc.Gyre Therapeutics Announces Publication in Journal of Gastroenterology and HepatologyNASDAQ:GYREGyre Therapeutics Inc
06/17/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GYRE

Your Recent History

USOTC
ENZC
Enzolytics (PK)
USOTC
WDLF
Decentral Life (PK)
USOTC
HIRU
Hiru (PK)
COIN
BTCUSD
Bitcoin
USOTC
AABB
Asia Broadband (PK)
USOTC
SGTM
Sustainable Green Team (PK)
NASDAQ
ILLR
Triller
USOTC
NBRI
North Bay Resources (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
COIN
XRPUSD
Ripple
USOTC
PHIL
PHI (PK)
NASDAQ
COOP
Mr Cooper
USOTC
FDCT
FDCTech (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
CGAC
Code Green Apparel (PK)
NASDAQ
LWLG
Lightwave Logic
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads